Besifovir is an oral antiviral medication approved for the treatment of chronic hepatitis B (CHB). Functioning as a nucleotide analog, it effectively suppresses the hepatitis B virus (HBV) while offering a significantly safer profile regarding bone density and kidney function compared to older standard treatments like tenofovir. It is grouped under the following drug class(es): DNA polymerase inhibitors, Nucleotides and Reverse Transcriptase Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include besifovirum. Its PubChem CID is 5270766.
Besifovir
| CAS No | 441785-25-7 |
|---|---|
| Molecular Formula | C10H14N5O4P |
| Molecular Weight | 299.22 g/mol |
| Synonyms | [1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Besifovir is an oral antiviral medication approved for the treatment of chronic hepatitis B (CHB).
The listed CAS number is 441785-25-7.
The listed molecular formula is C10H14N5O4P.
The listed molecular weight is 299.22 g/mol.
[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid.
The source lists besifovirum.